Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT04468061
This study is recruiting at 15 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (Trodelvy™;IMMU-132) Pembrolizumab (Keytruda®; MK-3475)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Triple Negative Breast Cancer
- PD-L1 Negative
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Dana-Farber Cancer Institute
- Last updated on ClinicalTrials.gov
- April 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Stamford Hospital · Stamford, CT
Florida · 2
- Miami Cancer Institute at Baptist Health (Kendall) · Miami, FL
- Miami Cancer Institute at Baptist Health · Plantation, FL
Illinois · 1
- University of Chicago Medical Center · Chicago, IL
Maine · 1
- Eastern Maine Medical Center · Brewer, ME
Massachusetts · 4
- Dana Farber Cancer Institute · Boston, MA
- DFCI @ Foxborough · Foxborough, MA
- DFCI @ Milford Regional Hospital · Milford, MA
- DF/BWCC in Clinical Affiliation with South Shore Hospital · South Weymouth, MA
North Carolina · 1
- The University of North Carolina at Chapel Hill · Chapel Hill, NC
Ohio · 2
- The Christ Hospital Cancer Center · Cincinnati, OH
- Ohio State University Medical Center · Columbus, OH
Pennsylvania · 1
- University of Pennsylvania-Abramson Cancer Center · Philadelphia, PA
South Carolina · 1
- Medical University of South Carolina · Charleston, SC
Tennessee · 1
- Sarah Cannon Research Institute · Chattanooga, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.